The Covid-19 pandemic placed unprecedented strain on the biopharmaceutical supply chain as the accelerated development of drugs and vaccines drove a surge in demand for raw materials. This demand outstripped the global manufacturing capacity of the entire supply chain resulting in shortages that were compounded by pandemic-driven challenges in logistics and staffing.
By March of 2020, we had determined that the global need for vaccines and therapeutics to combat the Covid-19 pandemic, in addition to the already expansive pipeline of non-Covid-related therapeutics, would require us to implement a substantial increase in our manufacturing capacity for the raw materials, assemblies, and technologies used by our customers.
Within the last two years, we initiated an ambitious multi-year expansion strategy aimed at increasing supply security through improving the resilience of our manufacturing operations. Continue reading to learn more about the fundamental principles of this strategy as well as it's execution to not only support the unprecedented mobilization of resources against the virus, but also ensure that the robustness and resilience is in place to protect against future crises.